Clinical Trial Update: Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo? [Phase 4]

View source ↗

Summary

A Phase 4 trial conducted by Radboud University Medical Center evaluating atorvastatin for reducing ischemia-reperfusion injury in humans has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Ischemia-reperfusion Injury

Drugs mentioned

• atorvastatin (atorvastatin)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Ischemia Reperfusion Injury, Cardiovascular Disease | Phase 4 | Status: COMPLETED